linjc16/ctgov huggingface dataset:
Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

Study Overview
=================
Brief Summary
-----------------
The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.

Official Title
-----------------
Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

Conditions
-----------------
Pollen Allergy

Intervention / Treatment
-----------------
* Other: blood withdrawal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens Male or female patients older than 18 years Written informed consent for providing blood and also to allow experimental manipulation Exclusion Criteria: Age < 18 years Any corticosteroids within the last three days Oral corticosteroid therapy within the last ten days Parenteral depot corticosteroids within the last three months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: blood withdrawal|Blood withdrawal|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibody profiling | Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients. | October 2018 - September 2021 |
Comparison of Core Muscle Asymmetry Using Spine Balance 3D in Patients With Arthroscopic Shoulder Surgery

Study Overview
=================
Brief Summary
-----------------
This study is an observational cross-sectional study. Post-operative patients need an immobilization period for a certain period of time after surgery. Kinetic chain changes due to immobilization can affect the symmetry of the core muscle. Therefore, in this study, core muscle asymmetry (CMA) is measured using a whole body tilt device for inpatients who have undergone arthroscopic shoulder surgery. We would like to make a clinical suggestion for post-operative rehabilitation by identifying the characteristics of CMA according to the left or right site.

Official Title
-----------------
Comparison of Core Muscle Asymmetry Using Spine Balance 3D in Patients With Arthroscopic Shoulder Surgery: A STROBE-compliant Cross-sectional Study

Conditions
-----------------
Muscle Disorder, Postoperative Pain, Shoulder Injuries, Immobilization, Asymmetric Limb Muscle Stiffness

Intervention / Treatment
-----------------
* Device: whole body tilt device (Spine Balance 3D)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: arthroscopic shoulder surgery limit of motion due to shoulder pain Exclusion Criteria: orthopedic surgery or other medical history in the lower extremities neurological history or are taking related medications chronic headache or disease related to the inner ear cardiovascular disease that may affect balance ability or take related medications acute dizziness when performing other balance training

Ages Eligible for Study
-----------------
Minimum Age: 26 Years
Maximum Age: 66 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arthroscopic shoulder surgery patients<br> | Device: whole body tilt device (Spine Balance 3D)<br>* The symmetry of the deep muscle was evaluated using a whole body tilt device (Spine Balance 3D, Cyber Medic Co., Ltd., Korea). Spine Balance 3D can evaluate the maintenance strength and maximum strength of the core muscles, and perform a personalized core muscle training program based on the evaluated results.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| direction core muscle ratio (DCMR) | DCMR was calculated as a percentage of time located in each direction. | 1 Day | 
| core muscle state ratio (CMSR) | CMSR was calculated as a percentage of the value compared to the reference data of healthy adults. | 1 Day |
Inflammation in Vascular Disease

Study Overview
=================
Brief Summary
-----------------
Increasing evidence suggests that systemic low-grade inflammation may be a driving force of cardiometabolic complications, such as vascular dysfunction, atherosclerosis and ischemic heart disease. Thus, we will investigate the role of inflammation in cardiovascular disease.

Detailed Description
-----------------
Vascular reconstruction surgeries usually require a small piece of the vessel wall to be excised. The excised vessel is generally discarded as medical waste: however, for patients participating in the study, the excised tissue will be placed in saline and collected for research use. Tissue collected from individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue will be cultured ex vivo in the presence or absence of therapeutic agents, to determine if these attenuate the inflammation associated with the atherosclerotic phenotype. Furthermore, the protocol will also be carried out using vascular tissue from control patients, which have undergone vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc).

Official Title
-----------------
The Role of Inflammation in Vascular Disease (Inflammationens Roll i kärlsjukdom)

Conditions
-----------------
Vascular Diseases, Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is planned to undergo vascular surgery. Signed informed consent has been obtained from the patient. Exclusion Criteria: Patient has difficulty to understand information. Patients under 18 years of age. Patients participating in any drug-related study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control patients<br>Control patients (n=20): In individuals undergoing vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc), a piece of healthy vessel must sometimes be removed in order to facilitate the surgical process. The vessel biopsies from this group will be categorized as healthy vessels in our study. | |
| Study patients<br>Study patients (n=150): In individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue is sometimes excised to facilitate the surgery. Biopsies from these individuals will be categorized as vessels with vascular dysfunction. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory status | The inflammatory status will be studied in patients with atherosclerotic disease. | 2019-2024 |
DM1 Heart Registry - DM1 Respiratory Registry

Study Overview
=================
Brief Summary
-----------------
Myotonic dystrophy type 1 (DM1) is the most frequent neuromuscular disease in adults. DM1 patients have an impaired prognosis (mean age of death <60 years) due to cardiac and respiratory complications. Our primary objective was to identify cardiac and respiratory prognostic factors in DM1.

Detailed Description
-----------------
Patients with genetically proven DM1 who were admitted in Pitié Salpêtrière Hospital from 2000 and 2010 will be identified. These patients systematically underwent neurological, cardiac and respiratory investigations. Baseline medical and genetic information will be entered in a dedicated database, including cardiac and respiratory investigations. The occurence of severe cardiac and respiratory adverse events will also be collected. Statistical analysis will be performed to look for correlations between baseline patient characteristics and cardiac or respiratory adverse events during follow up.

Official Title
-----------------
Cardiac and Respiratory Prognostic Factors in Patients With Myotonic Dystrophy Type 1

Conditions
-----------------
Myotonic Dystrophy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DM1 mutation (>50 CTG repeats) Age > 18 years Exclusion Criteria: Patient refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myotonic dystrophy, Prognosis, Sudden death, Respiratory failure
Validation of the O3 Regional Somatic Tissue Oxygenation Monitor

Study Overview
=================
Brief Summary
-----------------
Testing the absolute accuracy of the Masimo O3 regional oximeter in reading somatic tissue oxygenation in healthy volunteers under controlled hypoxia.

Official Title
-----------------
A Single-Center, Prospective Study in Healthy Volunteers for Validation of the O3 Regional Somatic Tissue Oxygenation Monitor

Conditions
-----------------
Oxygen Deficiency

Intervention / Treatment
-----------------
* Device: Masimo O3 Regional Oximeter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 45 years, inclusive Willing and able to provide written informed consent Healthy subjects Exclusion Criteria: Pregnant women Presence of any cardiovascular or pulmonary disease Exposure to high altitude(s) (>2000 m) within 30 days prior to the study Known allergy to intravenous contrast medium or heparin Subject has skin abnormalities affecting the digits such as psoriasis, eczema, angioma, scar tissue, burn, fungal infection, substantial skin breakdown, nail polish or acrylic nails that would prevent monitoring of SpO2 levels during the study Patients deemed not suitable for the study at the discretion of the Investigator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy Adult Volunteers<br>Controlled hypoxia will be induced and Masimo O3 regional oximeter-derived tissue oxygen saturation (rSO2) readings of somatic tissue will be measured. The readings will be compared with blood reference oxygen saturation values. | Device: Masimo O3 Regional Oximeter<br>* Study sensors will be placed on somatic tissues. Readings will be taken from the tissues underneath the O3 sensors.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of O3 Sensor by ARMS Calculation of Percent rSO2 | Accuracy of the sensors will be determined by comparing somatic regional oxygen saturation (rSO2) readings from the O3 sensor and blood reference oxygen saturation values and calculating the Arithmetic root mean square (ARMS). | 1 visit up to 8 hours |
Brain Energy Metabolism in Patients With Chronic Liver Disease and Impaired Central Nervous System

Study Overview
=================
Brief Summary
-----------------
The purpose of the current study is to look into the pathogenesis of a severe medical condition causing acute episodes on the central nervous system as seen in majority of patients with liver cirrhosis.

Official Title
-----------------
Brain Energy Metabolism in Patients With Acute Hepatic Encephalopathy Measured With PET

Conditions
-----------------
Cirrhosis, Hepatic Encephalopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 6 patients with liver cirrhosis with an acute episode of hepatic encephalopathy, 6 patients with liver cirrhosis without an acute episode of hepatic encephalopathy, 6 healthy subjects age and sex matched Exclusion Criteria: Neurological and/or psychiatric condition, Non-treated diabetes, Pregnancy/breast-feeding

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ammonia, Astrocytes, Citric acid cycle, Alpha ketoglutarate dehydrogenase
NHLBI Type II Coronary Intervention Study

Study Overview
=================
Brief Summary
-----------------
To determine whether lowering of cholesterol with cholestyramine in a population with Type II hyperlipidemia led to a decreased rate of progression (a regression of coronary artery disease) as demonstrated by death, myocardial infarction, or progression of disease on angiography.

Detailed Description
-----------------
BACKGROUND: There is overwhelming evidence that increased cholesterol levels are associated with increased risk of cardiovascular disease. This study examined whether lowering of cholesterol through drug therapy in people who had coronary artery disease as determined by angiography led to regression of the disease, again as indicated by angiography and reduction in mortality or nonfatal myocardial infarction. The study should be contrasted with the Coronary Primary Prevention Trial (CPPT), which determined whether lowering cholesterol through a combination of drug and diet therapy resulted in decreased cardiovascular mortality. It should be noted that patients in the CPPT did not have known preexisting coronary heart disease. DESIGN NARRATIVE: A randomized, double-blind trial, with single experimental and control groups. The experimental group received drug therapy (cholestyramine); the control group received placebo. Both groups received diet therapy. The endpoints were a significant difference in the progression of coronary disease as shown by angiography or a significant difference in new myocardial infarction or death. Patients were followed under therapy for at least 5 years.

Conditions
-----------------
Cardiovascular Diseases, Coronary Disease, Heart Diseases, Hypercholesterolemia, Familial, Myocardial Infarction, Myocardial Ischemia

Intervention / Treatment
-----------------
* Drug: cholestyramine


Participation Criteria
=================
Eligibility Criteria
-----------------
Men and women with angiographically demonstrated coronary artery disease.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: cholestyramine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the role of lung sonography during different PEEP settings in ICU patients with ARDS.

Detailed Description
-----------------
Acute respiratory distress syndrome (ARDS) is a clinical syndrome that often occurs in critically ill patients. Patients with ARDS invariably require mechanical ventilation to improve oxygen transport. An improvement in oxygenation can be obtained by an increase in positive end-expiratory pressure (PEEP). In critically ill patients with ARDS, lung imaging is been held by the use of chest radiography and the gold standard technique, Computed Tomography (CT). We designed an observational study in which we included patients under mechanical ventilation admitted in our ICU. In all patients PEEP changes were applied and lung sonography was performed.

Conditions
-----------------
ARDS

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critically ill patients with ARDS admitted in ICU of Evangelismos Hospital length of stay > 48 hours Exclusion Criteria: age < 18 years emphysema fractures or skin lesions that do not allow the implementation of lung sonography BMI > 35 kg/m2 length of stay < 48 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Non aerated lung area changes |  | 20 min after PEEP trial | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial oxygen and carbon dioxide partial pressure |  | 20 min after PEEP trial | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sonography, ICU, PEEP
Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to evaluate the performance of established and new risk predictors in predicting mortality in post-infarction patients suffering from diabetes mellitus

Official Title
-----------------
Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Diabetes Mellitus

Conditions
-----------------
Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute myocardial infarction, presence of sinusrhythm Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Assessment, Risk, Diabetes mellitus, Autonomic nervous system
Nutraceuticals and Drug Treatment in Frail Older Adults

Study Overview
=================
Brief Summary
-----------------
Frailty is a multidimensional condition due to reserve loss leading to physical and cognitive impairment that is very common in older adults; in fact, its incidence increases with age. Frail older adults present a high risk of adverse events such as disability, hospitalization and mortality. It is very important to check comorbidities and complications to reduce the incidence of cognitive and physical impairment.

Detailed Description
-----------------
Frailty is a multidimensional condition due to reserve loss leading to physical and cognitive impairment that is very common in older adults; in fact, its incidence increases with age. Frail older adults present a high-risk of adverse events such as disability, hospitalization and mortality. It is very important to check comorbidities and complications to reduce the incidence of cognitive and physical impairment; hence, clinical evaluation is the main goal to get an early diagnosis and a timely treatment for cognitive impairment. Considering this background, the study will investigate the effects of nutraceuticals and drug treatment on cognitive impairment in frail older adults. In this scenario, global cognitive function will be evaluated with Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) test and physical impairment with the Fried criteria and 5-metres gait speed test.

Official Title
-----------------
Cognitive and Physical Impairment in Frail Older Adults

Conditions
-----------------
Frailty

Intervention / Treatment
-----------------
* Other: Nutraceuticals


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 65 years; a frailty status. Exclusion Criteria: age < 65 years. no frailty status. left ventricular ejection fraction <25%, with previous myocardial infarction or previous PPCI or/and coronary by-pass grafting.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Frail older adults treated with nutraceuticals and drugs<br> | Other: Nutraceuticals<br>* To observe the effect on cognitive and physical impairment.<br>* Other names: amlodipine;|
| Frail older adults not treated with nutraceuticals and drugs<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Montreal Cognitive Assessment (MoCA) | Global cognitive impairment | July 2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 5 metres gait speed test | Physical impairment | July 2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
frailty, cognitive impairment, physical impairment, older adults